Node-sparing Modified Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Locally Advanced of Middle and Low Rectal Cancer : An Randomized, Prospective, Multicenter, Open-label, Phase III Clinical Trial (mRCAT-III)
Latest Information Update: 16 Jan 2025
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Tislelizumab (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms mRCAT-III
Most Recent Events
- 25 Jul 2024 New trial record